https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Int J Hyperthermia 2010;26(7):612-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Int J Hyperthermia 2010;26(7):612-72010-01-01 00:00:002010-01-01 00:00:00Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence: a review of the randomised data
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Int J Hyperthermia 2010;26(2):118-26
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Int J Hyperthermia 2010;26(2):118-262010-01-01 00:00:002010-01-01 00:00:00Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse: Results of a pilot study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / J. Virol. 2010 Jan;84(1):639-46
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / J. Virol. 2010 Jan;84(1):639-462010-01-01 00:00:002010-01-01 00:00:00The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-12-24 / J. Neurooncol. 2010 Jul;98(3):395-405
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-12-24 / J. Neurooncol. 2010 Jul;98(3):395-4052009-12-24 00:00:002009-12-24 00:00:00Transcranial electro-hyperthermia combined with alkylating chemotherapy in patients with relapsed high-grade gliomas: phase I clinical results
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-12-15 / Clin. Cancer Res. 2009 Dec;15(24):7726-7736
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-12-15 / Clin. Cancer Res. 2009 Dec;15(24):7726-77362009-12-15 00:00:002019-02-15 08:46:08Clinical Benefit of Allogeneic Melanoma Cell Lysate-Pulsed Autologous Dendritic Cell Vaccine in MAGE-Positive Colorectal Cancer Patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-12-01 / Endocr Metab Immune Disord Drug Targets 2009 Dec;9(4):328-43
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-12-01 / Endocr Metab Immune Disord Drug Targets 2009 Dec;9(4):328-432009-12-01 00:00:002019-02-15 08:44:08Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-12-01 / Int J Hyperthermia 2009 Dec;25(8):610-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-12-01 / Int J Hyperthermia 2009 Dec;25(8):610-62009-12-01 00:00:002019-02-15 09:17:30Heat shock proteins and immunity: application of hyperthermia for immunomodulation
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-12-01 / Cancer Treat. Rev. 2010 Apr;36(2):131-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-12-01 / Cancer Treat. Rev. 2010 Apr;36(2):131-412009-12-01 00:00:002019-02-15 08:53:00The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-12-01 / Expert Opin Biol Ther 2009 Dec;9(12):1565-75
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-12-01 / Expert Opin Biol Ther 2009 Dec;9(12):1565-752009-12-01 00:00:002019-02-15 09:23:56A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-11-20 / J. Gastroenterol. 2010 Apr;45(4):451-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-11-20 / J. Gastroenterol. 2010 Apr;45(4):451-82009-11-20 00:00:002019-02-15 09:02:54Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma
